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Abstract
Prions are responsible for a heterogeneous group of fatal neurodegenerative diseases. They occur
in three forms – sporadic, genetic, or acquired – and involve non-covalent post-translational
modifications of the cellular prion protein (PrPC). Prions (PrPSc) are characterized by their infectious
properties and intrinsic ability to act as a template, converting the normal, physiological PrPC into the
pathological form, PrPSc. The ‘protein-only’ hypothesis, postulated by Stanley B Prusiner, implies that
the generation of de novo prions is possible. Exciting recent work, in vivo and in vitro, has further
strengthened this postulate.
Introduction and context
Prions, proteinaceous infectious particles, or PrPSc, are
responsible for a heterogeneous group of fatal neuro-
degenerative diseases [1]. Prion diseases manifest as
sporadic, genetic, or acquired disorders, involving non-
covalent, post-translational modifications of the normal
cellular prion protein (PrPC, where the superscript C
stands for cellular) into PrPSc (where the superscript Sc
stands for scrapie, the prion disease that affects sheep) [2].
Prions are characterized by their infectious properties and
by the intrinsic ability of their secondary, tertiary, and
quaternary structures to act as a template and convert the
normal physiological PrPC into the pathological, disease-
causing form, PrPSc [3].
Major recent advances
In vitro support for de novo prions
The ‘protein-only’ hypothesis for prion propagation
implies that it should be possible to generate prions
in vitro from highly purified recombinant PrP (recPrP).
Several attempts have been made to confirm this
hypothesis, but the resulting prions had little or no
infectivity, as well as minimal or no protease digestion
resistance – two elements necessary to prove the ‘protein-
only’ hypothesis [4,5]. In recent years, the most striking
work supporting the ‘protein-only’ postulate has shown
that pure recPrP can be converted in vitro into a structural
form similar to prions [6-9]. When PrPSc is treated with
proteinase K (PK) and further processed, the N-terminal
region is removed, resulting in a PK-resistant core with
an apparent molecular mass of 27-30 kDa, called PrP27-
30 [10]. Legname et al. [6] produced truncated recombi-
nant mouse PrP (MoPrP), corresponding to PrP27-30,
and then converted this into amyloid fibrils. Amyloid
fibrils were intracerebrally inoculated into transgenic
(Tg) mice over-expressing the N-terminally truncated
form of MoPrP, MoPrP(89-231). These mice, called
Tg9949, express MoPrP(89-231) at levels 16 times higher
than the normal PrPC expressed in wild-type mice [11].
These inoculated fibrils caused neurological defects
between 380 and 660 days post-inoculation (DPI),
depending on the biochemical protocol applied [6].
Brain homogenates of mice inoculated with the amyloid
preparations exhibited the PK-resistant form of PrPSc.
Serial transmission of these brain homogenates caused
disease in transgenic and wild-type mice. Thus, the
synthetic prions generated using truncated recombinant
MoPrP demonstrated that PrP is necessary and sufficient
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for infectivity [6]. This seminal work has further
contributed to our understanding of the biochemical
and biophysical characteristics of prions, indicating
the existence of an inverse correlation between the
stability and infectivity of prion isolates [8]. Colby and
colleagues [9] took this work a step further; they
produced an array of PrP amyloids with different
conformational stabilities and found that the inverse
relationship between stability and incubation time was
still valid. The most stable prion strains exhibited the
longest incubation times, whereas more labile amyloids
revealed shorter incubation times [9]. More recently,
Colby and colleagues [12] isolated protease-sensitive
synthetic prion (sPrPSc). Often, PrPSc is protease-resistant
but sPrPSc has been isolated in humans and other
animals. Colby et al. reported that sPrPSc was generated
in vitro during polymerization of recPrP into amyloid
fibers. In 22 independent experiments, recPrP amyloid
preparations, but not recPrP monomers or oligomers,
transmitted disease to Tg9949 mice (n = 164). In addi-
tion, they inoculated three synthetic prion isolates into
Tg4053 mice that overexpress full-length MoPrP. Tg4053
mice are not prone to developing spontaneous neuro-
logical dysfunction [13]. The resulting synthetic prion
isolates caused disease in 600-750 DPI in Tg4053 mice,
which exhibited sPrPSc. These novel synthetic prions
demonstrate that conformational changes in wild-
type PrP can produce prions composed exclusively of
sPrPSc [12].
More recently, Makarava et al. [14] showed additional
experimental evidence that synthetic prions can be
generated when amyloid fibrils produced from full-
length recombinant Syrian hamster (SHa) PrP were
intracerebrally inoculated in SHa animals.
Castilla and colleagues generated infectious scrapie
prions [15] using the protein misfolding cyclic amplifi-
cation (PMCA) in vitro system [16]. PMCA is a procedure
involving cyclic amplification of PrP misfolding that
allows rapid conversion of large excess PrPC into a
protease-resistant, prion-like form in the presence of low
quantities of PrPSc template [16]. In the experiment of
Castilla et al., 263K-infected (SHa-adapted scrapie form
of prion) SHa brain homogenates were subjected to 20
PMCA cycles in the presence of PrPC. Although no
molecules of the original scrapie brain homogenate were
present in samples, biochemical and structural properties
of the in vitro-amplified samples still revealed the same
features of 263K prions. In particular, the amplified
sample was PK-resistant, highly insoluble in non-
denaturant detergent (such as 10% sarkosyl), and
enriched in b-sheet content. The PK-resistant-inoculated
animals died at around 170 DPI showing the typical
signs of scrapie. To verify the PK-resistant in vitro-
generated stability over time, serial transmissions were
carried out; animals inoculated with this material
exhibited neurological dysfunction and died after a
mean of 136.5 DPI.
To investigate the mechanism of prion formation,
Deleault et al. [17] conducted a series of experiments
using the PMCA in vitro system in the presence of
co-purified lipids and polyanions. They generated PrPSc
de novo from the simple combination of PrPC, co-
purified lipids, and simple polyanions [17,18], although
some questions were raised of whether generation of
de novo prions from standard PMCA methodology
might be due to cross-contamination from existing
prions [4].
The PMCA in vitro system has also been used to
propagate prion strains [19-21]. Numerous PMCA
amplifications were carried out using, as a seed, different
mouse-adapted (RML [Rocky Mountain Laboratory],
ME7, 139A and 79A), human (vCJD [variant Creutz-
feldt-Jakob disease]), bovine (301C), SHa (263K), and
cervid (CWD [chronic wasting disease]) prion strains.
Biochemical analyses – PK digestion, glycosylation ratio,
and electrophoresis mobility – of end products revealed
the same strain features as the original seeds, suggesting
that strains are dependent on the properties of PrPSc
[19-21]. PMCA was also employed with prions from
various species in combination with transgenic mice to
study, and even overcome, the prion species barrier
[19,21]. De novo in vitro generation of PrPSc from PrPC
and poly(A)RNA using the PMCA system has opened up
new ways to investigate the molecular mechanisms
underlying the spontaneous misfolding of the PrP and
its propagation. To convert de novo PrPC from healthy
SHa and mouse brain homogenates into its infectious
isoform, Barria and colleagues [4] modified the PMCA
conditions, increasing the number of PMCA cycles.
Animals inoculated with this PK-resistant PrP showed
abnormalities after an average incubation period of
112.6 days and revealed spongiform degeneration,
astroglyosis, and PrP accumulation. Even more recently,
Wang et al. [22] employed PMCA under standard
conditions (cycles) and produced prions from bacterially
expressed recombinant MoPrP(23-230) in the presence
of the synthetic anionic phospholipid 1-palmitoyl-2-
oleoylphosphatidylglycerol and RNA (as a polyanion).
These prions were protease-resistant. When injected into
wild-type mice, this new aggregated and pathogenic PrP
isoform induced neurological signs after about 130 DPI,
with the terminal phase occurring around 150 DPI [22].
Nevertheless, upon second passage the newly discovered
prion isolate did not lead to abbreviation or stabilization
Page 2 of 4
(page number not for citation purposes)
F1000 Biology Reports 2010, 2:46 http://f1000.com/reports/biology/content/2/46
of incubation times in mice, casting doubts about the
identification of novel synthetic prions.
In vivo de novo prions
The existence of human genetic prion diseases, in which
patients with mutations in the open-reading frame of the
human PrP gene, PRNP (PRioN Protein), spontaneously
develop prion disease (transmissible in most forms),
strongly supports the ‘protein-only’ hypothesis [23,24].
Additionally, many transgenic mice with mutations
homologous to human prion diseases also develop
spontaneous disease that is often transmissible [25].
Transgenic mice carrying mutations and over-expressing
PrP mutants spontaneously develop neurological symp-
toms similar to those of prion disorders, but their brain
homogenates are infectious only for mice carrying the
same mutation, and not for wild-type mice [5,26,27].
Therefore, it has been argued in the prion field as to
whether this represents true de novo prion generation, or
merely an acceleration of disease [28].
Recently, Sigurdson and coworkers [29] developed a
transgenic mouse over-expressing two novel mutations in
the MoPrP gene, Prnp; these change two amino acids into
those normally present in the elk PrP primary sequence
that confer a rigid structure to the b2-a2 loop in the
protein. Although they created this transgenic mouse to
study the role of the rigid-loop structure, surprisingly they
found that thesemice, called transgenic rigid loop (RL)-PrP
mice, developed spontaneous prion disease at variable
time points, with a 50% incidence by 364 DPI. Sick RL-PrP
mice showed ataxia, weight loss, lethargy, kyphosis, and
hind limbparalysis, while their brains showed PrP deposits
in the stratum lacunosum-moleculare of the hippocampus,
within the corpus callosum, and in the cingulum. Due to a
transmission barrier, RL-PrP mice inoculated with wild-
type prion strains exhibited prolonged incubation time
before developing prion disease. Therefore, the authors
did not attempt to transmit transgenic RL-PrP prions
directly to wild-type mice; rather, they stabilized the prion
isolate from RL-PrP mice by passaging it in mice over-
expressing wild-type PrP, called Tga20 mice [30]. Tga20
mice inoculated with brain homogenates from sick RL-PrP
mice developed neurologic signs by 481 DPI. Serial
passages into Tga20 mice of brain homogenates from
RL-PrP-infected Tga20mice caused similar symptoms with
a shorter incubation period. Moreover, both PK resistance
and conformational stability increased after each passage.
After serial passaging in Tga20mice, these de novo generated
prionswere transmissible towild-typemice [29]. This is the
first time that prions generated spontaneously in mice
models are able to infect mice carrying a wild-type
sequence.
Future directions
In order to define a prion, one needs to fulfill four
criteria: transmissibility into recipient animals, neuro-
pathological features (e.g., gliosis, vacuolation, immuno-
positive PrP deposits) [31], biochemical features, such as
PK resistance [32], and stability (defined by resistance to
denaturation with chaotropic agents, such as guadinium
HCl) [33]. The strain of a prion is determined by these
characteristics. Now, we can design synthetic prions with
defined biophysical characteristics and predict their
infectivity [9]. A major frontier in prion research is to
determine the precise structural properties of the prion at
the molecular level, such as differences in secondary,
tertiary, and quaternary structures among different
strains that confer defined prion strain characteristics.
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